Day One

• Phase 1 study of a viral-vectored individualised neoantigen vaccine in HNSCC
• Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
• Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach

• How to manufacture efficiently on a tight clock? 
• Considerations for a successful CMC approach through case studies
• Analytical aspects

• Designing combination studies to measure incremental benefits of neoantigen therapies when added to checkpoint inhibitors, focusing on recurrence-free survival and overall response rates
• Using immune monitoring and biomarker analysis to demonstrate enhanced T-cell activation, tumour infiltration, and durable anti-tumour immunity beyond standard-ofcare effects
• Highlighting trial strategies, including patient stratification and adaptive endpoints, to clearly differentiate the added clinical value of neoantigen therapies over existing treatments

• Presentation of CellVax’s Tumour Presenting Cell (TPC) platform, a personalised cancer vaccine approach that leverages the patient’s own tumour cells to present the full repertoire of tumour antigens without the need for neoantigen prediction algorithms
• Clinical and translational insights from the ongoing Phase 2 trial of FK-PC101 in high risk prostate cancer patients following prostatectomy, including immune activation signals and long-term immunological responses
• How a tumour-derived antigen presentation may enable a simpler, faster, and potentially more scalable pathway for personalised cancer vaccines compared to sequencing-driven neoantigen approaches

• Highlighting a novel vaccine platform used to develop both off-the-shelf and personalised peptide vaccines
• Evaluating HLA genotype as predictive biomarker for in vitro measured immunogenicity of peptide vaccines
• Showcasing correlation studies for the identification of a candidate predictive biomarker

The Personalis NeXT Platform integrates deep tumor tissue genomic profiling with ultrasensitive plasma-based monitoring to support neoantigen-based immunotherapy development.

• ImmunoID NeXT delivers comprehensive immunogenomic profiling from tumor tissue, enabling accurate neoantigen selection through validated exome/transcriptome assays, and neoantigen predictions trained on immunopeptidomics data.
• NeXT Personal is a tumor-informed, plasma-based assay for detecting molecular residual disease, molecular response, and recurrence earlier, with longitudinal variant tracking for real-time insight into disease progression.
• Together, these assays provide a unified view from tumor to blood, enhancing precision oncology strategies.

• Current evidence supporting neoantigen-based therapies and their evolving role in precision oncology 
• The scientific, manufacturing, and operational challenges—and potential solutions
• Clinical infrastructure, patient pathways, regulatory considerations, and multidisciplinary collaboration needed to integrate neoantigen therapies into standard oncology care

• VB10.NEO induces strong immunity and tumour protection in preclinical studies
• Streamlined manufacturing process to reduce turnaround time
• Robust immunity in advanced cancer patients highlights DNA-encoded neoantigen vaccine potency

Present a poster to showcase your latest research and ensure your work is directing the conversation. This is your chance to exchange ideas, explore fresh perspectives, and dive into cutting-edge data with fellow authors and attendees.

•  Clinical learnings from GT-30, including the favourable safety profile observed with a personalised neoantigen immunotherapy regimen even in advanced hepatocellular carcinoma patients treated in combination with pembrolizumab
• The scientific and development rationale for moving into GT-31, an adjuvant monotherapy study in hepatocellular carcinoma patients with no active radiographic disease, where lower tumour burden and immune priming may provide a stronger setting for benefit
• Key design considerations for personalised neoantigen trials in hepatocellular carcinoma, including novel endpoint strategy, surveillance and recurrence assessment, feasibility of individualised manufacturing, and how to generate a package that is both clinically meaningful and developmentally scalable

• Therapeutic cancer vaccines often fail to deliver durable clinical benefit because they stimulate only limited parts of the anti-tumour immune response.
• Effective vaccination requires validated tumour targets, strong immune stimulation, reliable manufacturing, and integration with modern immuno-oncology treatments.
• Black Canyon Bio’s SNAPduo™ platform combines shared tumour antigens, validated personalised neoantigens, and a potent adjuvant to enhance T-cell activation and potentially improve checkpoint inhibitor outcomes in HPV-associated and other solid tumours

• Evaluating how combination therapies can enhance tumour-specific immune responses
• Overcoming challenges with increased toxicity, complex dosing schedules, and variable patient responses to maximise effectiveness of combined regimens
• Discussing strategies to optimise trial design, biomarker selection, and patient stratification to maximise the benefits of combination therapies